This is a reply to a comment that Coyle (2020) made on our article entitled "Which valued-based price when patients are heterogeneous?" (Levaggi and Pertile, 2020).

A reply to "Who would benefit from average value-based pricing?"

Paolo Pertile
2021

Abstract

This is a reply to a comment that Coyle (2020) made on our article entitled "Which valued-based price when patients are heterogeneous?" (Levaggi and Pertile, 2020).
contract theory
drug price
health economics
public economics
regulation
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1048114
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact